UniQure针对某类ALS的基因疗法得到安全点头,计划进行更多的患者试验。 UniQure's gene therapy for a specific ALS type gets safety nod, plans more patient trials.

UniQure是一家基因治疗公司,它接受一个独立委员会对其AMT-162治疗某类ALS的安全性审查。 UniQure, a gene therapy company, received a positive safety review for its AMT-162 treatment for a specific type of ALS from an independent committee. 疗法针对的是SOD1基因突变引起的ALS。 The therapy targets ALS caused by mutations in the SOD1 gene. 该公司计划在2025年第一季度招收更多的病人,以进一步检验治疗的安全和潜在效果。 The company plans to enroll more patients in the first quarter of 2025 to further test the safety and potential effectiveness of the treatment.